title: Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro.
abstract: Targeted drug delivery to cancer cells by use of antibody-conjugated liposomes (immunoliposomes) has attracted considerable interest in recent years. Despite increasing efforts in developing immunoliposomes as drug carriers, the investigation of useful tumor-associated antigen targets is far from complete. Carbonic anhydrase IX (CA IX) is a cell surface antigen characterized by hypoxia-induced expression in many solid tumors. This study investigated the feasibility of CA IX-directed immunoliposomes for targeted delivery of docetaxel to human lung cancer cells in vitro. Docetaxel-loaded immunoliposomes targeting CA IX were developed with an encapsulation efficiency of 84.4±3.9% and an average particle size of 143.9±11.1 nm. Using fluorescence-based flow cytometry, the in vitro binding activity of the immunoliposomes was found to be significantly higher (by 1.65-fold) than that of the nontargeted liposomes in CA IX-positive lung cancer cells, whereas no such difference was observed between the two groups when CA IX was not expressed. Furthermore, immunoliposomal docetaxel exhibited the strongest growth inhibitory effect against CA IX-positive lung cancer cells when compared with nontargeted liposomal docetaxel or free docetaxel solution. These data suggested that CA IX-directed immunoliposomes could serve as a promising drug delivery system for targeted killing of lung cancer cells.
authors.affiliation: School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong.
authors.forename: Blenda Chi Kwan
authors.initials: BC
authors.lastname: Wong
authors.affiliation: School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong.
authors.forename: Hongqi
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong.
authors.forename: Ling
authors.initials: L
authors.lastname: Qin
authors.affiliation: School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong.
authors.forename: Hubiao
authors.initials: H
authors.lastname: Chen
authors.affiliation: School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong.
authors.forename: Chen
authors.initials: C
authors.lastname: Fang
authors.affiliation: School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong.
authors.forename: Aiping
authors.initials: A
authors.lastname: Lu
authors.affiliation: School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong.
authors.forename: Zhijun
authors.initials: Z
authors.lastname: Yang
mesh_terms: D000951:Antigens, Neoplasm / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D000077143:Docetaxel; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D005240:Feasibility Studies; D005434:Flow Cytometry; D006801:Humans; D008081:Liposomes; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010316:Particle Size; D043823:Taxoids / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D043823:Taxoids; D000077143:Docetaxel; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases
keywords: cancer chemotherapy; cell surface antigen; conjugation; hypoxia; liposome; nanotechnology
references.citation: J Pharmacol Exp Ther. 2008 Jan;324(1):95-102
references.pmid: 17947497
references.citation: J Clin Oncol. 2001 Aug 15;19(16):3660-8
references.pmid: 11504747
references.citation: Drug Discov Today. 2006 Sep;11(17-18):812-8
references.pmid: 16935749
references.citation: Mol Hum Reprod. 2001 Jul;7(7):611-6
references.pmid: 11420383
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):473-7
references.pmid: 16428489
references.citation: Br J Cancer. 2003 Sep 15;89(6):1067-71
references.pmid: 12966427
references.citation: Am J Pathol. 2001 Mar;158(3):1011-9
references.pmid: 11238049
references.citation: Neurosci Lett. 2008 Feb 27;432(3):184-7
references.pmid: 18241990
references.citation: Gastroenterology. 1997 Feb;112(2):398-408
references.pmid: 9024293
references.citation: Curr Pharm Des. 2004;10(24):2981-9
references.pmid: 15379663
references.citation: Adv Exp Med Biol. 2011;701:115-22
references.pmid: 21445777
references.citation: Biochim Biophys Acta. 2000 Dec 20;1509(1-2):299-310
references.pmid: 11118541
references.citation: J Immunother Emphasis Tumor Immunol. 1996 May;19(3):184-91
references.pmid: 8811493
references.citation: World J Urol. 2011 Feb;29(1):121-6
references.pmid: 20512580
references.citation: J Clin Oncol. 2003 Feb 1;21(3):473-82
references.pmid: 12560438
references.citation: Curr Opin Mol Ther. 2006 Feb;8(1):39-45
references.pmid: 16506524
references.citation: Cancer Chemother Pharmacol. 2011 Nov;68(5):1179-90
references.pmid: 21400240
references.citation: Jpn J Cancer Res. 2001 Oct;92(10):1138-45
references.pmid: 11676866
references.citation: Curr Opin Oncol. 2011 Mar;23(2):140-9
references.pmid: 21178617
references.citation: Neurosci Lett. 2002 Nov 29;333(3):212-6
references.pmid: 12429385
references.citation: J Control Release. 2010 Dec 1;148(2):135-46
references.pmid: 20797419
references.citation: Histochem Cell Biol. 2000 Sep;114(3):197-204
references.pmid: 11083462
references.citation: Cancer Res. 1997 Jul 15;57(14):2827-31
references.pmid: 9230182
references.citation: Int J Nanomedicine. 2006;1(3):297-315
references.pmid: 17717971
references.citation: Clin Cancer Res. 2003 Nov 15;9(15):5532-9
references.pmid: 14654533
references.citation: Br J Cancer. 2010 May 25;102(11):1627-35
references.pmid: 20461082
references.citation: Biochim Biophys Acta. 2001 Aug 6;1513(2):207-16
references.pmid: 11470092
references.citation: J Control Release. 1998 Apr 30;53(1-3):25-37
references.pmid: 9741911
references.citation: Am J Pathol. 1998 Jul;153(1):279-85
references.pmid: 9665489
references.citation: Clin Cancer Res. 2004 Jul 1;10(13):4464-71
references.pmid: 15240538
references.citation: J Huazhong Univ Sci Technolog Med Sci. 2005;25(3):279-81
references.pmid: 16201271
references.citation: Eur Respir J. 1999 Oct;14(4):806-11
references.pmid: 10573225
references.citation: Biochim Biophys Acta. 1999 Apr 14;1418(1):232-8
references.pmid: 10209227
references.citation: Curr Pharm Des. 2010;16(29):3255-63
references.pmid: 20819068
references.citation: Eur Respir J. 2005 Oct;26(4):657-61
references.pmid: 16204597
references.citation: Nat Biotechnol. 2007 Oct;25(10):1165-70
references.pmid: 17891134
references.citation: Clin Cancer Res. 2006 Mar 1;12(5):1507-14
references.pmid: 16533775
references.citation: Cancer Res. 2000 Dec 15;60(24):7075-83
references.pmid: 11156414
references.citation: Curr Pharm Des. 2008;14(7):685-98
references.pmid: 18336315
references.citation: Cancer Res. 2001 Sep 1;61(17):6394-9
references.pmid: 11522632
references.citation: J Control Release. 2011 Feb 28;150(1):2-22
references.pmid: 21095210
references.citation: Nat Rev Drug Discov. 2005 Feb;4(2):145-60
references.pmid: 15688077